CEO and Managing Partner at Seventure Partners · Joined 2001
View Live Interactive Profile →Isabelle de Cremoux is CEO and Managing Partner of Seventure Partners (Presidente du directoire) and heads its Life Sciences department, covering the thematic verticals health, food, nutrition, digital health and microbiome, sport and wellness and the blue economy, and the thematic funds Health For Life Capital, Sport et Performance Capital and Blue Forward Fund. She began her career in 1991 with Arthur Andersen in Detroit, then spent six years at Pfizer France and Pfizer Europe in management, clinical research and business development, and in 1998 joined Laboratoire Fournier / Abbott as Deputy Director of Business Development. She joined Seventure in 2001 to establish the Life Sciences division and was the founder of the Health for Life Capital fund, which Seventure says was created in partnership with Danone and Novartis and focuses primarily on the microbiome. Her Seventure bio names Santaris (sold to Roche for USD 450 million in August 2014), ArgenX (listed), OPI (sold to Eusa for EUR 110 million), Bioalliance (listed), Pixium Vision (listed), Biophytis (listed), Metabolic Explorer (listed) and Cambrooke (sold to Ajinomoto) among her investment experiences, and says she is currently responsible for Enterome Biosciences, MaaT Pharma, Polaris, Targedys, Vedanta and Foodsmart. She holds an engineering degree from Ecole Centrale Paris and DECF and ISEB qualifications. Her Seventure bio states she is one of the six members of the French Conseil de l'innovation and non-executive chairman of the private-equity investment branch of the French AFG professional association. Enterome's own board bio page states she has served on Enterome's board since 2008 and also serves as a director of Limm Therapeutics, Ysopia, TargEDys, Polaris and MaaT Pharma SA; MaaT Pharma's own About us page lists her as a Non-Executive Director.